Active quarter for Diamyd Medical


Press Release, January 30, 2009                                                 

Active quarter for Diamyd Medical                                               

In today's quarterly report Diamyd Medical's President and CEO, Elisabeth       
Lindner, comments on the very active period the company has had during the last 
part of 2008.                                                                   

During the last quarter the company has focused on meeting and negotiating with 
both the scientific and financial sector. On the scientific side the company    
achieved one of its milestones; the successful Phase II study with children and 
adolescents with type 1 diabetes was published in the prestigious medical       
journal the New England Journal of Medicine. Together with leading diabetes     
researchers the company has also applied to initiate two of each other          
independent prevention studies, where the diabetes vaccine Diamyd® will be      
tested in order to prevent type 1 diabetes in persons at high risk of developing
the disease.                                                                    

“The highest priority for the company right now is to secure continued financing
and to recruit patients to the ongoing Phase III studies in the US and Europe”, 
says Elisabeth Lindner, President and CEO of Diamyd Medical. “We are actively   
pursuing outlicensing of our products and are also evaluating other partnership 
opportunities with companies that work in the area of autoimmune diabetes.”     


For more information, please contact:                                           
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.),                 
elisabeth.lindner@diamyd.com                                                    
Phone: +46-8-661 00 26                                                          


For pictures and press material, please contact:                                
Sonja Catani, Chief Communications Officer Diamyd Medical AB (publ.),           
sonja.catani@diamyd.com                                                         
Phone: +46-8-661 00 26                                                          

This information is disclosed in accordance with the Securities Markets Act, the
Financial Instruments Trading Act or demands made in the exchange rules.        

Diamyd Medical is a Swedish biopharmaceutical company focusing on development of
pharmaceuticals for treatment of autoimmune diabetes and its complications. The 
company's most advanced project is the GAD-based drug Diamyd® for type 1        
diabetes and for which Phase III trials are ongoing in both the US and Europe.  
Furthermore, the company has started clinical studies within chronic pain, using
its Nerve Targeting Drug Delivery System (NTDDS). The company has also          
out-licensed the use of GAD for the treatment of Parkinson's disease.           

Diamyd Medical has offices in Sweden and in the US. The share is quoted on the  
OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker:  
DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further  
information is available on the company's web site: www.diamyd.com

Attachments

eng_q1.pdf